Gemini Therapeutics (GMTX)

Gemini Therapeutics Stock Analysis & Ratings

GMTX Stock Chart & Stats

Day’s Range$1.4 - $1.52
52-Week Range$1.16 - $12.95
Previous Close$1.47
Average Volume (3M)273.42K
Market Cap$60.95M
P/E Ratio-0.9
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-1.58



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Gemini Therapeutics’s price range in the past 12 months?
Gemini Therapeutics lowest stock price was $1.16 and its highest was $12.95 in the past 12 months.
    What is Gemini Therapeutics’s market cap?
    Gemini Therapeutics’s market cap is $60.95M.
      What is Gemini Therapeutics’s price target?
      The average price target for Gemini Therapeutics is $1.88. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $2.00 ,the lowest forecast is $1.50. The average price target represents 33.33% Increase from the current price of $1.41.
        What do analysts say about Gemini Therapeutics?
        Gemini Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 4 Wall Streets Analysts.
          When is Gemini Therapeutics’s upcoming earnings report date?
          Gemini Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 87 days.
            How were Gemini Therapeutics’s earnings last quarter?
            Gemini Therapeutics released its earnings results on May 12, 2022. The company reported -$0.352 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.052.
              Is Gemini Therapeutics overvalued?
              According to Wall Street analysts Gemini Therapeutics’s price is currently Undervalued.
                Does Gemini Therapeutics pay dividends?
                Gemini Therapeutics does not currently pay dividends.
                What is Gemini Therapeutics’s EPS estimate?
                Gemini Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Gemini Therapeutics have?
                Gemini Therapeutics has 43,230,000 shares outstanding.
                  What happened to Gemini Therapeutics’s price movement after its last earnings report?
                  Gemini Therapeutics reported an EPS of -$0.352 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went up 0.685%.
                    Which hedge fund is a major shareholder of Gemini Therapeutics?
                    Currently, no hedge funds are holding shares in GMTX


                    Gemini Therapeutics Stock Analysis

                    Smart Score
                    Price Target
                    ▲(33.33% Upside)
                    The Gemini Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Gemini Therapeutics

                    FS Development Corp is a blank check company.

                    Similar Stocks
                    No data currently available

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis